EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma

Xiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, Virginie Verkarre, Cheng-Ming Sun, Wenxuan Cheng, Li Xu, Fangrong Yan, Salma Kotti, Wolf Hervé Fridman, Catherine Sautes-Fridman, Stéphane Oudard und 1 weitere

Journal for ImmunoTherapy of Cancer · 2025-01 · 13 (1) · e010386

DOI: 10.1136/jitc-2024-010386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.01.2025. Verfasst von Xiaofan Lu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer and Functional Genomics, Institute of Genetics and Molecular and Cellular Biology (IGBMC), CNRS/INSERM/UNISTRA, Illkirch-Graffen…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Endogenous Retroviruses, Immunotherapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation ARC pour la Recherche sur le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endogenous retrovirus (ERV) elements are genomic footprints of ancestral retroviral infections within the human genome. While the dysregulation of ERV transcription has been linked to immune cell infiltration in various cancers, its relationship with immune checkpoint inhibitor (ICI) response in solid tumors, particularly metastatic clear-cell renal cell carcinoma (ccRCC), remains inadequately explored.

Methods

This study analyzed patients with metastatic ccRCC from two prospective clinical trials, encompassing 181 patients receiving nivolumab in the CheckMate trials (−009 to –010 and −025) and 48 patients treated with the ipilimumab-nivolumab combination in the BIONIKK trial. ERV expression was quantified using the ERVmap algorithm from RNA sequencing data. Our primary objective was to correlate ERV expression with progression-free survival, with overall survival and time-to-second-treatment survival as secondary endpoints. We used bootstrap methods with univariate Cox regression on 666 substantially expressed ERVs to evaluate their prognostic significance and stability.

Results

Our analysis centered on two ERVs, E4421_chr17 and E1659_chr4, which consistently exhibited opposing prognostic impacts across both cohorts. We developed a stratification system based on their median expression levels, categorizing patients into four ERV subgroups. These subgroups were further consolidated into a three-tier risk model that significantly correlated with ICI treatment outcomes. The most responsive ERV risk category showed enhanced endothelial cell infiltration, whereas the resistant category was characterized by higher levels of myeloid dendritic cells, regulatory T cells, myeloid-derived suppressor cells, and markers of T-cell exhaustion. Notably, this ERV-based classification outperformed traditional transcriptomic signatures in predicting ICI efficacy and showed further improvement when combined with epigenetic DNA methylation markers.

Conclusions

Our findings introduce a dual ERV-based stratification system that effectively categorizes patient risk and predicts clinical outcomes for ccRCC patients undergoing ICI therapy. Beyond enhancing the predictive precision of existing transcriptomic models, this system paves the way for more targeted and individualized approaches in the realm of precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsEndogenous RetrovirusesImmunotherapyImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedPrognosisAgedProspective Studies

Stichwörter der Autor:innen

BiomarkerImmune Checkpoint InhibitorsImmunotherapyKidney CancerTumor microenvironment - TME

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Cancer and Functional Genomics, Institute of Genetics and Molecular and Cellular Biology (IGBMC), CNRS/INSERM/UNISTRA, Illkirch-Graffenstaden, France.
  • Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP, Université Paris Cité, Paris, France.
  • Centre de Recherche Cordeliers, Université de Paris Cité, Sorbonne Université, Equipe labellisée Ligue contre le Cancer, Paris, France.
  • Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pathology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP, Université Paris Cité, Paris, France.
  • Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.

Förderung

  • Fondation ARC pour la Recherche sur le Cancer

Zitieren

APA

Lu, X., Vano, Y. A., Su, X., Verkarre, V., Sun, C. M., Cheng, W., Xu, L., Yan, F., Kotti, S., Fridman, W. H., Sautes-Fridman, C., Oudard, S., & Malouf, G. G. (2025). Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer, 13(1), e010386. https://doi.org/10.1136/jitc-2024-010386

Vancouver

Lu X, Vano YA, Su X, Verkarre V, Sun CM, Cheng W, et al. Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 2025;13(1):e010386. doi:10.1136/jitc-2024-010386

BibTeX
@article{Lu2025,
  author = {Lu, Xiaofan and Vano, Yann-Alexandre and Su, Xiaoping and Verkarre, Virginie and Sun, Cheng-Ming and Cheng, Wenxuan and Xu, Li and Yan, Fangrong and Kotti, Salma and Fridman, Wolf Hervé and Sautes-Fridman, Catherine and Oudard, Stéphane and Malouf, Gabriel G},
  title = {Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {1},
  pages = {e010386},
  doi = {10.1136/jitc-2024-010386}
}
Kostenlos starten →